Skip to content
Subscriber Only

Myriad’s Human-Gene Patent Rehearing Ordered by High Court

The U.S. Supreme Court ordered a lower court to revisit whether human genes can be patented in light of the justices March 20 decision that limited the ability to obtain legal protection for some diagnostic medical tests.

The justices today ordered the U.S. Court of Appeals for the Federal Circuit to reconsider its decision that allowed patents on genetic material used in Myriad Genetics Inc. tests for breast and ovarian cancer.